|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A phase II trial of nab-paclitaxcl (ABI-007) and carboplatin in patients with unrvsect- able stage IV melanoma: a North Central Cancer Treatment Group Study, N057H 显示文摘 | Kottschade LA Suman V J Amatruda T 3rd ct al | 2011 | Cancer2011，117，8： | 1 |
| 2 | A phase II trial of nab-paclitaxcl (ABI-007) and carboplatin in patients with unrvsect- able stage IV melanoma: a North Central Cancer Treatment Group Study, N057H 显示文摘 | Kottschade LA Suman V J Amatruda T 3rd ct al | 2011 | Cancer2011，117，8： | 1 |
| 3 | Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma 显示文摘 | Senzer NN Kaufman HL Amatruda T | 2009 | J Clin Oncol2009，27，34： | 1 |
| 4 | A phase II trial of nab-paclitaxel(ABI-007) and carboplatin in pa- tients with unresectable stage 1V melanoma:a North Cen- tral Cancer Treatment Group Study, N057E (1) 显示文摘 | Kottschade LA Suman VJ Amatruda T | 2011 | Can- cer2011，117，8： | 1 |
| 5 | Phase Ⅱ clinical trial of a granulocyte-macrophage colony-stimulating factorencoding,second-generation oncolytic herpes virus in patients with unresectable metastatic melanoma显示文摘 | Senzer NN Kaufman HL Amatruda T | 2009 | J Clin Oncol2009，27，34： | 1 |
| 6 | Distinct forms of the {beta} subunit of G TP-binding regulatory proteins identified by molecular cloning 显示文摘 | Fong H K W Amatruda T T Birren B W | 1987 | PNAS USA1987，84，11： | 1 |
| 7 | A phase Ⅱ trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage Ⅳ melanoma: a North Central Cancer Treatment Group Study,N057E(1)显示文摘 | Kottschade LA Suman VJ Amatruda III T | 2011 | Cancer2011，117，8： | 1 |
| 8 | A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unreseetable stage IV melanoma 显示文摘 | Kottschade LA Suman V J Amatruda T 3rd | 2011 | Cancer2011，117，8： | 1 |
| 9 | Phase 11 clinical trial of a granuloeyte-maerophage colony-stimulat- ing factor-encoding, second-generation oneolytic her- pesvirus in patients with unresectable metastatic melanoma显示文摘 | Senzer NN Kaufman HL Amatruda T | 2009 | J Clin Oncol2009，27，34： | 1 |
| 10 | Phase II clinical trial of a ranulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma 显示文摘 | Senzer NN Kaufman HL Amatruda T | 2009 | J Clin Oncol2009，27，34： | 1 |
| 11 | Phase Ⅱ clinical trial of a granulocyte-macrophage colony-stimulating factor-enco- ding, second-generation oneolytic herpesvirus in patients with unre- sectable metastatic melanoma 显示文摘 | Senzer NN Kaufman HL Amatruda T | 2009 | J Clin Oncol2009，27，34： | 1 |
| 12 | A phase Ⅱ trial of nab-paclitaxel (ABI 007) and carboplatin in patients with unresectable stage IV melanoma a north central cancer treatment group study, N057E显示文摘 | Kottschade L A Suman V J Amatruda T | 2011 | Cancer2011，117，8： | 1 |
| 13 | OPTiM : A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous ( SC ) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma 显示文摘 | ANDTBACKA RHI COLLICHIO FA AMATRUDA T | 2013 | J Clin Ortcal2013，31，18： | 1 |
| 14 | Phase Ⅱ trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in paients with unresectable stage Ⅳ melanoma显示文摘 | Perez DG Suman V Amatruda T | 2007 | J Clin Oncol2007，25，18： | 1 |
| 15 | Phase II clini-cal trial with a second generation,GM-CSF encoding,on-colytic herpesvirus in unresectable metastatic melanoma显示文摘 | Senzer NN Kaufman H Amatruda T | 2009 | J Clin Oncol2009，27，15： | 1 |
| 16 | Final planned overalI survival (OS/from optim, a randomized phase Ill trial of talimogenc laherparepvec (T-Vet) versus GM-CSF lbr the treatment of unresected stage II1B/C/IV melanoma (NCT00769704)显示文摘 | Andtbacka R H Collichio F A Amatruda T | 2014 | J hnmunother Cancer2014，2，3： | 1 |
| 17 | Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding,second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma显示文摘 | Senzer N N Kaufman H L Amatruda T Nemunaitis M Reid T Daniels G Gonzalez R Glaspy J Whitman E Harrington K Goldsweig H Marshall T Love C Coffin R Nemunaitis J J | 2009 | J Clin Oncol2009，27，34： | 1 |
| 18 | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma显示文摘 | Andtbacka R H Kaufman H L Collichio F Amatruda T Senzer N Chesney J Delman K A Spitler L E Puzanov I Agarwala S S Milhem M Cranmer L Curti B Lewis K Ross M Guthrie T Linette G P Daniels G A Harrington K Middleton M R Miller W H Jr Zager J S Ye Y Yao B Li A Doleman S Vanderwalde A Gansert J Coffin R S | 2015 | J Clin Oncol2015，33，25： | 1 |
| 19 | A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)显示文摘 | Kottsehade LA Suman VJ Amatruda T 3rd | 2011 | Cancer2011，117，8： | 1 |
| 20 | Phase Ⅱ clinical trial of a granulocyte-macrophage colony-stimulating factorencoding,second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma显示文摘 | Senzer NN Kaufman HL Amatruda T | | 0，，34： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员